We’re experiencing issues with our datasets and search. We apologise for any inconvenience while we work to fix this.
TAVNEOS (Vifor Pharma Pty Ltd)
Product name
TAVNEOS
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
202 (255 working days)
Active ingredients
avacopan
Registration type
NCE/NBE
Indication
Tavneos, in combination with a rituximab or cyclophosphamide based regimen, is indicated for the treatment of adults with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]).
Registration process
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.